Ketamine Transiently Alters Brain Network Dynamics Linked to Rumination and Somatosensory Processing
September 22, 2026
Ketamine produces rapid antidepressant effects and has been report...
Read More
Enezumab Shows Sustained Real-World Benefits in Difficult-to-Treat Migraine
September 19, 2026
Migraine prevention can be particularly challenging in patients wit...
Read More
DT120 Lysergide ODT Receives FDA Breakthrough Therapy Designation for Major Depressive Disorder
September 15, 2026
Definium Therapeutics announced on September 8, 2026, that the US F...
Read More
World Suicide Prevention Day
September 10, 2026
Education matters for suicide prevention. National and regional sui...
Read More
Lithium Treatment May be Associated With Lower Cardiovascular Risk in Bipolar Disorder
September 8, 2026
Lithium remains a first-line treatment with established benefits fo...
Read More
SGLT2 Inhibitor Use Associated With Lower Dementia Risk in Older Adults With Psychiatric Disorders
September 5, 2026
A recent study suggest that sodium-glucose cotransporter 2 (SGLT2) ...
Read More
Suicide Prevention: Cross-Diagnostic Strategies in Clinical Care
September 1, 2026
Join us at the 2026 NEI Fall Congress, for a CME/CE session presen...
Read More
GLP-1 Receptor Agonists Are Associated With Lower Mortality in Serious Mental Illness
August 28, 2026
People with serious mental illness (SMI) die 10 to 25 years earlier...
Read More
Treating Parental ADHD May Strengthen Behavioral Intervention for Young Children
August 21, 2026
Attention-deficit/hyperactivity disorder (ADHD) is highly heritable...
Read More
FDA Clears Blood Test for Alzheimer’s Disease Evaluation in Adults as Young as 40
August 20, 2026
The U.S. Food and Drug Administration (FDA) cleared C2N Diagnostics...
Read More
Benzodiazepine Trends Reveal Persistent Challenges in Older Adult Care
August 17, 2026
Benzodiazepines are often prescribed to older adults for anxiety an...
Read More
DT120 (Lysergide) Shows Positive Phase 3 Results in Generalized Anxiety Disorder
August 13, 2026
Definium Therapeutics reported positive Phase 3 topline results for...
Read More